Opinion

Video

Exciting Pipeline Therapeutics for Parkinson Disease

An expert discusses upcoming advancements in Parkinson disease treatments, including the potential release of the ND0612 pump later this year, demonstrating efficacy comparable to oral carbidopa/levodopa, the dopamine agonist tavapadon, CVN424 as a novel therapy not targeting the dopamine pathway, and ongoing stem cell and gene therapy developments, with stem cells capable of creating dopamine-producing cells entering phase 3 studies.

Related Videos
1 expert in this video
1 expert in this video
Cheryl Kyinn, PA-C
© 2025 MJH Life Sciences

All rights reserved.